A214450 Stock Overview
Operates as a biopharmaceutical company primarily in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for A214450 from our risk checks.
My Notes
Capture your thoughts, links and company narrative
PharmaResearch Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩253,500.00 |
| 52 Week High | ₩267,000.00 |
| 52 Week Low | ₩86,800.00 |
| Beta | 0.52 |
| 1 Month Change | 27.77% |
| 3 Month Change | 27.90% |
| 1 Year Change | 130.45% |
| 3 Year Change | 225.00% |
| 5 Year Change | 607.11% |
| Change since IPO | 121.40% |
Recent News & Updates
What PharmaResearch Co., Ltd.'s (KOSDAQ:214450) 32% Share Price Gain Is Not Telling You
Dec 19
PharmaResearch Co., Ltd. (KOSDAQ:214450) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Aug 15Recent updates
What PharmaResearch Co., Ltd.'s (KOSDAQ:214450) 32% Share Price Gain Is Not Telling You
Dec 19PharmaResearch Co., Ltd. (KOSDAQ:214450) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Aug 15Here's Why We Think PharmaResearch (KOSDAQ:214450) Might Deserve Your Attention Today
May 21PharmaResearch Co., Ltd.'s (KOSDAQ:214450) 33% Share Price Surge Not Quite Adding Up
Apr 09Is Pharma Research Products (KOSDAQ:214450) A Risky Investment?
Mar 23Are Investors Undervaluing Pharma Research Products Co., Ltd (KOSDAQ:214450) By 50%?
Mar 05Should You Be Adding Pharma Research Products (KOSDAQ:214450) To Your Watchlist Today?
Feb 17Introducing Pharma Research Products (KOSDAQ:214450), A Stock That Climbed 65% In The Last Year
Feb 02
Pharma Research Products Co., Ltd (KOSDAQ:214450) Is Yielding 0.5% - But Is It A Buy?
Jan 20Here's What Pharma Research Products Co., Ltd's (KOSDAQ:214450) Shareholder Ownership Structure Looks Like
Jan 07Declining Stock and Solid Fundamentals: Is The Market Wrong About Pharma Research Products Co., Ltd (KOSDAQ:214450)?
Dec 23Is Pharma Research Products (KOSDAQ:214450) Using Too Much Debt?
Dec 08Is Pharma Research Products Co., Ltd (KOSDAQ:214450) Trading At A 43% Discount?
Nov 25Shareholder Returns
| A214450 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 3.5% | -3.9% | -3.7% |
| 1Y | 130.5% | 15.6% | -10.4% |
Return vs Industry: A214450 exceeded the KR Biotechs industry which returned 15.6% over the past year.
Return vs Market: A214450 exceeded the KR Market which returned -10.4% over the past year.
Price Volatility
| A214450 volatility | |
|---|---|
| A214450 Average Weekly Movement | 7.9% |
| Biotechs Industry Average Movement | 8.7% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in KR Market | 12.7% |
| 10% least volatile stocks in KR Market | 3.3% |
Stable Share Price: A214450 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A214450's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 409 | Sang-Soo Jung | www.pharmaresearch.co.kr/kor/ |
PharmaResearch Co., Ltd., together with its subsidiaries, operates as a biopharmaceutical company primarily in South Korea. The company offers Re-An eye drops for protecting eyes from corneal damages with various causes; JBP PLAMON injection, a brown ampoule containing a pale yellow transparent liquid; ZADAXIN injection, an adjunctive therapy for influenza vaccination in immunocompromised elderly patients; PLACENTEX injection for the treatment and tissue restoration of wounds; CLEVIEL VOLUME to temporarily improve facial wrinkles in adults through the physical restoration; Rejuran HB plus which is used for temporary improvement of adult's crow's feet wrinkles; Rejuvenex injection, a tissue regeneration activator that regenerates connective tissues, including ligament, tendon, skin, etc.; and Rejuvenex cream, which treats the wound through rapid tissue regeneration. It also provides REJURAN, a medical device for face (especially eye, perioral area), neck, Décolleté, hands, etc; CLEVIEL prime plus and contour plus with lidocaine medical devices; D+CELL 350 TRA I; and REJURAN moisturizer for daily skin protection, as well as REJUVENEX SCULPT V; REJURAN concentrate for sensitive and aged skin; REJURAN healing eye gel and mask; REJURAN sunscreen that protects skin from UV rays; and REJURAN recover soothing mask.
PharmaResearch Co., Ltd. Fundamentals Summary
| A214450 fundamental statistics | |
|---|---|
| Market cap | ₩2.63t |
| Earnings (TTM) | ₩88.76b |
| Revenue (TTM) | ₩317.00b |
29.7x
P/E Ratio8.3x
P/S RatioIs A214450 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A214450 income statement (TTM) | |
|---|---|
| Revenue | ₩317.00b |
| Cost of Revenue | ₩92.01b |
| Gross Profit | ₩224.99b |
| Other Expenses | ₩136.23b |
| Earnings | ₩88.76b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 8.54k |
| Gross Margin | 70.97% |
| Net Profit Margin | 28.00% |
| Debt/Equity Ratio | 5.2% |
How did A214450 perform over the long term?
See historical performance and comparisonDividends
0.4%
Current Dividend Yield11%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 06:25 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
PharmaResearch Co., Ltd. is covered by 14 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sae-rom Lee | Daishin Securities Co. Ltd. |
| Jonghyun Park | DAOL Investment & Securities Co., Ltd. |
| Tae-Na Jo | Eugene Investment & Securities Co Ltd. |